Clinical Trial Detail

NCT ID NCT03932409
Title Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (FIERCE)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors University of Oklahoma
Indications

endometrial carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.